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ABSTRACT
High bone mass (HBM) can be an incidental clinical ﬁnding; however, monogenic HBM disorders (eg, LRP5 or SOST mutations) are
rare. We aimed to determine to what extent HBM is explained bymutations in knownHBMgenes. A total of 258 unrelated HBM cases
were identiﬁed from a review of 335,115 DXA scans from 13 UK centers. Cases were assessed clinically and underwent sequencing of
known anabolic HBM loci: LRP5 (exons 2, 3, 4), LRP4 (exons 25, 26), SOST (exons 1, 2, and the van Buchem’s disease [VBD] 52-kb
intronic deletion 30). Familymemberswere assessed for HBM segregationwith identiﬁed variants. Three-dimensional proteinmodels
were constructed for identiﬁed variants. Two novel missense LRP5 HBM mutations ([c.518C>T; p.Thr173Met], [c.796C>T;
p.Arg266Cys]) were identiﬁed, plus three previously reported missense LRP5 mutations ([c.593A>G; p.Asn198Ser], [c.724G>A;
p.Ala242Thr], [c.266A>G; p.Gln89Arg]), associated with HBM in 11 adults from seven families. Individuals with LRP5 HBM
(prevalence 5/100,000) displayed a variable phenotype of skeletal dysplasia with increased trabecular BMD and cortical thickness
on HRpQCT, and gynoid fatmass accumulation on DXA, comparedwith both non-LRP5HBMand controls. Onemostly asymptomatic
woman carried a novel heterozygous nonsense SOSTmutation (c.530C>A; p.Ser177X) predicted to prematurely truncate sclerostin.
Protein modeling suggests the severity of the LRP5-HBM phenotype corresponds to the degree of protein disruption and the
consequent effect on SOST-LRP5 binding. We predict p.Asn198Ser and p.Ala242Thr directly disrupt SOST binding; both correspond
to severe HBM phenotypes (BMD Z-scores þ3.1 to þ12.2, inability to ﬂoat). Less disruptive structural alterations predicted from
p.Arg266Cys, p.Thr173Met, and p.Gln89Arg were associated with less severe phenotypes (Z-scores þ2.4 to þ6.2, ability to ﬂoat).
In conclusion, although mutations in known HBM loci may be asymptomatic, they only account for a very small proportion (3%)
of HBM individuals, suggesting the great majority are explained by either unknown monogenic causes or polygenic inheritance.
© 2015 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals, Inc. on behalf of the American Society for
Bone and Mineral Research.
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Introduction
Worldwide, fewer than 30 families have been reported withlow density lipoprotein receptor-related protein 5 (LRP5)
high bone mass (HBM) (MIM# 603506). LRP5, a ubiquitous cell
membrane co-receptor, mediates canonical Wnt signaling and,
in bone, facilitates osteoblastic bone formation.(1) The 10
documented gain-of-function LRP5 mutations reported to
date all lie in exons 2, 3, and 4, which collectively code for the
ﬁrst b-propeller domain, reducing binding afﬁnity with SOST
(sclerostin) and Dickkopf 1.(2–18) In contrast, loss-of-function
LRP5 mutations cause osteoporosis pseudoglioma syndrome
(OPPG; MIM# 259770), an autosomal recessive condition of
congenital blindness and severe childhood osteoporosis with
skeletal fragility.(19)Heterozygous carriers have been reported to
have low bone mineral density (BMD).(20) Most OPPG and low
BMD–associated mutations have been described in the second
and third b-propeller domains.(16) Loss-of-function SOST muta-
tions cause sclerosteosis, a rare condition of excessive bone
overgrowth (MIM# 269500); a downstream deletion is thought
to be responsible for the milder phenotype of van Buchem’s
disease (VBD) (MIM# 239100).(21,22) Both LRP5-related and
SOST-related HBM have been associated with bone overgrowth,
mandible enlargement, oral tori, cortical thickening, poor
buoyancy, and importantly, reduced fracture risk.(2) Although
sclerosteosis confers a severe phenotype with craniotomy
occasionally required to relieve rising intracranial pressure
from skull overgrowth, LRP5 HBM has a variable phenotype and
may be asymptomatic.(2–4) Recently, LRP4mutations, thought to
impair SOST-LRP4 interaction, have been reported in a
phenotype resembling sclerosteosis.(23) Anti-sclerostin anti-
bodies are now in phase 3 clinical trials,(24,25) and other
inhibitors of osteoblastic Wnt antagonists are in development
as novel anabolic osteoporosis treatments.(26–29) Such develop-
ments exemplify the valuable insights gained from studying rare
monogenic conditions. To date, however, no study has
employed a systematic approach to establish the frequency or
scope of HBMmutations and their associated phenotypeswithin
the general population.
We have previously reported the clinical characteristics of a
unique population of adults with unexplained HBM, identiﬁed
from review of 335,115 historical dual-energy X-ray absorptiom-
etry (DXA) scans across 13 UK National Health Service (NHS)
centers for BMD Z-scores or T-scores þ4.(30) Within this
population, we aimed to determine the genetic causes of HBM
by sequencing unrelated HBM cases for mutations in known
anabolic HBM loci, namely LRP5 (exons 2, 3, and 4), LRP4 (exons
25 and 26), and SOST (exon 1, the coding region of exon 2, and
the VBD 52-kb intronic deletion occurring 35 kb downstream of
SOST). We then aimed to determine the phenotypes associated
with such mutations and relate these to predicted three-
dimensional protein models.
Subjects and Methods
Identification of HBM cases
The HBM study is a UK-based multicentered observational study
of adults with unexplained HBM, identiﬁed incidentally upon
routine clinical DXA scanning. Full details of DXA database
screening and participant recruitment have been reported(30)
(Supporting Information S1). Brieﬂy, DXA databases containing
335,115 DXA scans were searched for individuals with a BMD
T-score or Z-scoreþ4 at any sitewithin the lumbar spine or hip,
at 13 NHS hospitals in England and Wales (nine Hologic, four
Lunar). A further two centers with Hologic scanners contributed
23 similar individuals identiﬁed prospectively. All 1505 DXA
images with BMD T-score or Z-score þ4 were visually
inspected; 962 cases with osteoarthritis and/or other causes of
raised BMD were excluded (eg, surgical metalwork, Paget’s
disease, metastases(31)). A generalized HBM trait would be
expected to affect both spine and hip BMD, though not
necessarily to the same extent. Hence we reﬁned our deﬁnition
of HBM index cases as: (1) L1 Z-score of þ3.2 plus total hip
Z-score ofþ1.2; or (2) total hip Z-scoreþ3.2 plus L1 Z-score of
þ1.2 (using age and gender-adjusted BMD Z-scores). A
threshold of þ3.2 was consistent with the only published
precedent for identifying HBM using DXA;(3) and also most
appropriately differentiated generalized HBM from artifact.(32) A
standard deviation of þ3.2 would be expected to identify a tail
of 0.069% of a normal distribution.(33)
Of 533 unexplained HBM index cases invited, 258 (48.4%)
agreed to participate.(30) Index cases were asked to invite their
ﬁrst-degree relatives and spouse/partner(s) to participate. HBM
status was deﬁned in ﬁrst-degree relatives as summed L1 plus
total hip Z-score of þ3.2.(30) Family-based controls comprised
relatives with BMD below this threshold. HBM among spouses
was deﬁned as for index cases. Participants were excluded if
under 18 years of age, pregnant, or unable to provide written
informed consent for any reason. All participants were clinically
assessed using a standardized structured history and examina-
tion, with phlebotomy for bone biochemistry, bone turnover
markers (Supporting Information S2) and DNA collection. DXA
scans were performed according to themanufacturer’s standard
scanning and positioning protocols. Where available, total
body (TB) BMD, fatmass (FM) (including android and gynoid FM),
and lean mass were measured as reported previously,(34) and
high-resolution pQCT (HRpQCT) was performed (Supporting
Information S2). Of note, no index cases who reported ever
having fractured had radiologic, hematologic, or clinical features
consistent with osteopetrosis.(30) Written informed consent was
obtained for all participants in line with the Declaration of
Helsinki(35) and this studywas approved by the BathMulti-centre
Research Ethics Committee (REC: 05/Q2001/78) and each NHS
Local REC.
Sanger sequencing for HBM mutations
DNA was extracted from peripheral venous blood using
standard phenol/chloroform extraction. PCR ampliﬁcation of
LRP5 (exons 2, 3, and 4), LRP4 (exons 25 and 26), and SOST (exon
1, the coding region of exon 2, and the VBD-associated 52-kb
intronic deletion 35 kb 30 of SOST) was performed on 50 ng
genomic DNA in a reaction mix consisting: 10 Immolase
reaction buffer, 10mM dNTPs, 50mM MgCl2, 5mM each primer,
0.5 U Immolase polymerase Taq (Bioline Reagents Ltd, London,
UK), and water to ﬁnal volume of 25mL. PCR cycling conditions
and primer sequences are shown in Supporting Information S3.
Samples were Sanger sequenced using standard techniques
(BigDye v3.1 chemistry; Life Technologies Corporation, Carlsbad,
CA, USA), and capillary sequenced (3130 Genetic Analyzer; Life
Technologies Corporation). Electrophoretograms were analyzed
using sequence analyses software Genalys v2.0b.(36) Variants
were examined in online databases: NCBI dbGene/dbSNP
(release 135), 1000 Genomes (www.1000genomes.org), UCSC
(GRCh37/Hg19), Leiden Open Variation Database (LOVD)
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(www.lovd.nl), Exome Variant Server (http://evs.gs.washington.
edu/EVS), and ExAC (http://exac.broadinstitute.org), using tran-
scripts LRP5: ENSP00000294304, SOST: ENST00000301691, and
LRP4: ENSG00000134569. We performed in silico functional
prediction using PolyPhen,(37) SIFT,(38) PMut,(39) and Mutation
Taster(40) bioinformatic prediction algorithms. When the same
point mutation was identiﬁed in more than one family,
haplotypes were compared between index case samples
genotyped using an Inﬁnium OmniExpress-12v1.0 GWAS chip
read using an Illumina iScan (Illumina, San Diego, CA, USA), with
genotype clustering performed using Illumina BeadStudio
software.
Protein modeling
Structural models of the LRP5-SOST complex were prepared
from the homologous structure of the LRP6 complex (PDB code
3SOV).(41) Mutations were introduced using the modeling
program ICM-Pro (Molsoft, San Diego, CA, USA) with local
minimization to optimize side chain positions within 7 Å of the
mutation site.(42)
Statistical analysis
HBM cases were grouped by mutation type for quantitative
analyses in comparison with (1) HBM cases lacking LRP5/SOST/
LRP4mutations and (2) family controls. Descriptive statistics are
presented as mean (95% conﬁdence interval [CI]) for continuous
and count (percentages) for categorical data. Linear regression
was used to analyze continuous variables and generate
standardized b coefﬁcients and 95% CIs. Age, gender,
menopausal status, and estrogen replacement therapy in
women were considered a priori confounders; weight and
height were additional potential confounders. Data were
managed using Microsoft Access (Microsoft Corp., Redmond,
WA, USA) (data entry checks; error rate <0.12%) and analyzed
using Stata release 12 statistical software (StataCorp, College
Station, TX, USA).
Results
LRP5
We identiﬁed two novel missense LRP5mutations ([c.518C>T; p.
Thr173Met], [c.796C>T; p.Arg266Cys]) as well as three previous-
ly reported missense LRP5 mutations ([c.593A>G; p.Asn198Ser],
[c.724G>A; p.Ala242Thr], [c.266A>G; p.Gln89Arg]), associated
with HBM in 11 adults among seven families (Table 1,
Supporting Information S4). All LRP5 mutations were heterozy-
gous and segregated with HBM in available pedigrees
(Supporting Information S5). Of 11 carrying a heterozygous
LRP5 mutation, none had sustained a low-trauma or moderate-
trauma adult fracture, six reported an inability to ﬂoat, seven had
oral tori, and eight had a noticeably enlargedmandible (Table 1).
LRP5 HBM quantitative analyses
The 11 HBM cases with LRP5mutations (“LRP5 HBM cases”) were
compared with 347 HBM cases without LRP5 mutations (250
index cases, 94 affected ﬁrst-degree relatives, and three spouses
who fulﬁlled HBM index case criteria) (“non-LRP5 HBM cases”),
and 200 family controls. Eight and four HBM cases had TB DXA
andHRpQCT performed respectively. LRP5HBM caseswere taller
than both non-LRP5 HBM cases and controls, with larger shoe
size and substantially greater BMD at all measured sites,
representing greater trabecular density and cortical thickness
measured by HRpQCT (Table 2). LRP5 HBM cases were also
heavier than controls, with greater fat mass, particularly gynoid
fat. After adjustment for age, gender, menopause, and estrogen
replacement in women, the LRP5 HBM cases remained
substantially taller than both non-LRP5 HBM cases and controls
(Supporting Information S6). Hence, analyses were further
adjusted for height; LRP5HBM cases still had persistently greater
BMD at all measured sites, as well as greater gynoid fat mass
than controls (Table 3). Further adjustment for total weight
highlighted a difference in gynoid fat mass between HBM cases
and both controls and non-LRP5 HBM cases (Supporting
Information S7). Although still within the normal reference
range, after adjustment mean adjusted calcium, was higher
among LRP5 HBM cases; however, bone turnover marker levels
were not discernibly different (Table 3).
Individual LRP5 HBM Phenotypes
All clinical cases listed in Table 1 are described in detail in
Supporting Information S7. Our most extreme HBM case, with
femoral neck T-score þ12.2, had presented at age 19 years
when he fainted and hit his head on a toilet seat, and in doing
so broke the toilet seat; cranial imaging showed a markedly
thickened skull (Fig. 1A; Supporting Information S5). He has a
heterozygous c.593A>G; p.Asn198Ser mutation that is
predicted to be functionally deleterious by three of four in
silico prediction tools; ie, suggesting decreased antagonism of
Wnt signaling with subsequent increased Wnt activity
(Table 1).
The most frequent LRP5 mutation, c.724G>A; p.Ala242Thr,
was identiﬁed in three unrelated families (with different LRP5
haplotypes), explaining ﬁve HBM cases in total, and is predicted
to be functionally deleterious by three of four in silico prediction
tools (Table 1, Fig. 1B, C). Interestingly, the novel mutation
c.796C>T; p.Arg266Cys, was identiﬁed in a 65 year old man with
a 25 year history of ulcerative colitis, for which he had been
treated with glucocorticoids almost continuously for 21 years,
despite which his HBM persisted; his bone turnover markers
were normal (Supporting Information S5).
A heterozygous c.266A>G; p.Gln89Arg mutation was identi-
ﬁed in an active man aged 69 years, with mild left hip
osteoarthritis; he has never fractured. A novel c.518C>T; p.
Thr173Met mutation was identiﬁed in a man aged 76 years, with
osteoarthritis of knees, hands, and hips (unilateral hip replace-
ment age 66 years), who had sustained two very-high-impact
fractures age 39 years (ﬁbula) and 48 years (elbow); the latter
required ulna nerve decompression 18 years later with ongoing
restrictions in the range of movement.
LRP5 protein modeling
The p.Asn198Ser mutation directly affects the SOST interaction
site and is predicted to disrupt SOST binding and inhibition,
resulting in a severe HBM phenotype (Fig. 2A). Modeling
suggests that the shorter serine side chain is too distant to
establish the two hydrogen bonds to SOST N40 (Asn40) that
are formed by the wild-type N198 (Asn198) side chain (Fig. 2B).
The similarly severe p.Ala242Thr mutation is predicted instead
to disrupt the core packing of the LRP5 structure, thereby
destabilizing the SOST binding site. The larger threonine side
chain is likely to introduce steric clashes with the proximal
F241 (Phe241) and M282 (Met282) (Fig. 2C). The alanine at the
LRP5 p.Ala242 position is conserved in LRP6 (p.Ala229),
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Table 1. Exonic Mutations Identiﬁed After Sanger Sequencing of all 258 HBM Index Cases With Clinical Characteristics and In Silico Functional Predictions
Pedigree Gene Mutation Exon
Amino
acid
change
Age
(years) Gender
Z-score
total
hip
Z-score
L1
Adult
fracture
Enlarged
mandible Tori
Nerve
compression
Sinks/
floats
(S/F) Polyphen
SIFT
(score) PMut Mutation taster
GERP
score
1 LRP5 593A>G 3 Asn198Ser 30 M þ12.2 þ8.3 N Ya Y N S Probably
damaging
Damaging Neutral Disease-causing 3.66
1 LRP5 593A>G 3 Asn198Ser 26 F þ6.8 þ5.6 N Ya N N S Probably
damaging
Damaging Neutral Disease-causing 3.66
1 LRP5 593A>G 3 Asn198Ser 66b M þ10.2 þ7.8 N Y Y N S Probably
damaging
Damaging Neutral Disease-causing 3.66
2 LRP5 724G>A 4 Ala242Thr 49 F þ7.1 þ10.7 N Y Y N S Probably
damaging
Damaging Neutral Disease-causing 3.78
2 LRP5 724G>A 4 Ala242Thr 21 M þ6.4 þ8.2 N N n/a N F Probably
damaging
Damaging Neutral Disease-causing 3.78
3 LRP5 724G>A 4 Ala242Thr 21 F þ7.1 þ6.0 N Yc Y Yd S Probably
damaging
Damaging Neutral Disease-causing 3.78
4 LRP5 724G>A 4 Ala242Thr 64 F þ5.9 þ8.1 N Y Y Ye S Probably
damaging
Damaging Neutral Disease-causing 3.78
4 LRP5 724G>A 4 Ala242Thr 41 F þ3.1 þ3.1 N Y Y N F Probably
damaging
Damaging Neutral Disease-causing 3.78
5 LRP5 C796C>Tf 4 Arg266Cysf 65 M þ2.5 þ6.2 N Y Y N F Probably
damaging
Tolerated Pathological Disease-causing -0.44
6 LRP5 266A>G 2 Gln89Arg 69b M þ2.4 þ4.6 N N N Yg n/ah Benign Tolerated Neutral Disease-causing 4.48
7 LRP5 518C>Tf 3 Thr173Metf 76 M þ3.6 þ4.2 Yi N N Yj F Probably
damaging
Tolerated Neutral Disease-causing 1.67
8 SOST 530C>Af 2 Ser177Xf 70 F þ1.7 þ3.5 N Y n/a N S n/a Tolerated n/a Disease-causing 4.26
In silico functional predictions relate to decreases in antagonism of Wnt signaling and hence increased Wnt activity.
HBM¼high bone mass; GERP¼Genomic Evolutionary Rate Proﬁling; n/a¼not available.
aWith prognatism.
bHistory of glucocorticoid treatment with oral bisphosphonate use.
cEnlarged and asymmetric.
dTightly packed brain gyri on MRI; cranial nerves V and VII mildly impaired.
eConductive deafness.
fNovel HBM mutation.
gCarpel tunnel syndrome.
hNon-swimmer.
iFibula aged 39, elbow aged 48, both very high impact fractures.
jUlna nerve decompression.
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suggesting that tight packing in this region is favored. The site
of the p.Ala242Thr mutation is only 10 Å from the SOST
peptide binding site allowing even minor structural rearrange-
ments to exert a negative effect on this interaction.
The mutations, p.Arg266Cys, p.Gln89Arg, and p.Thr173Met,
were associated with less severe HBM phenotypes. p.Arg266 is
located on the opposite face of the b-propeller from the SOST
binding site (Fig. 2A) and is unlikely to directly disrupt its
structure or to interfere directly with its binding (Fig. 2D).
Potentially, the introduction of an exposed cysteine residue
could induce inappropriate disulphide bond formation result-
ing in misfolding and aberrant trafﬁcking of the mutant
protein.
The p.Gln89Arg mutation introduces an arginine side chain,
which is found naturally at the equivalent position in wild-type
LRP6. However, the local packing around this site differs
between the two proteins with the absence of a neighboring
acidic residue in LRP5. The p.Gln89 position in LRP5 also appears
more tightly packed due to the presence of both p.Y78 (Tyr78)
and p.Y91 (Tyr91) (Fig. 2E). Nonetheless, modeling suggests that
the mutant arginine side chain can be tolerated. p.Gln89Arg is a
reported SNP (rs41494349) with minor allele frequency (MAF)
0.02% in 1000 Genomes (0.1% MAF in East Asians, 0.005% in
Europeans (ExAC)).
The p.Thr173Met mutation site lies in one of the b-propeller
loops that line the SOST binding site giving potential for disruption.
However, p.Thr173 is distinct from the known peptide site and
the side chain is likely to be oriented away from the peptide
interface making no direct contact with it (Fig. 2F). Moreover, the
methionine substitution is predicted to be well tolerated. Thus,
the less severe phenotypes associated with individuals carrying
the p.Arg266Cys, p.Gln89Arg, and p.Thr173Met mutations may
be due to less disruptive structural alterations. Models with DKK1
rather than SOST drew similar conclusions.
SOST
We identiﬁed a novel heterozygous nonsense variant in exon 2
(c.530C>A; p.Ser177X) in a woman aged 70 years who reported
difﬁculty ﬂoating (pedigree 8; Table 1). She had no symptoms of
cranial nerve impingement, no syndactyly, and was 166 cm in
height. This variant (cDNA.C577A, at chr17:41832822) is listed as
rs143571358 in dbSNP135 and ExAC, with MAF of 0.04% and
0.0009% respectively. This base is highly conserved, with a
Table 2. Clinical Characteristics of LRP5 HBM Cases, Non-LRP5 HBM Cases, and Family Controls
LRP5 HBM
(n¼ 11)
Non-LRP5 HBM
(n¼ 347)
Controls
(n¼ 200)
Mean (SD) Mean (SD) Mean (SD)
Age (years) 49.5 (21.0) 61.9 (13.5) 54.0 (16.1)
Height (cm) 178.1 (8.6) 166.3 (8.6) 171.1 (10.2)
Weight (kg) 93.7 (13.5) 84.8 (17.5) 82.4 (17.3)
BMI (kg/m2) 29.5 (2.8) 30.7 (6.0) 28.0 (4.9)
Shoe sizea 9.8 (2.3) 7.0 (1.9) 7.9 (2.3)
Total hip BMD Z-score 5.8 (2.7) 3.0 (1.1) 0.5 (0.9)
L1 BMD Z-score 6.4 (2.0) 3.9 (1.5)
 0.5 (1.2)
TB BMD (mg/cm2)b 1.76 (0.32) 1.33 (0.10) 1.21 (0.12)
TB lean mass (kg)b 55.4 (11.7) 46.7 (10.1) 51.3 (11.4)
TB fat mass (kg)b 37.9 (6.5) 35.4 (12.8) 29.0 (11.3)
TB android fat mass (kg)b 3.72 (0.54) 3.43 (1.41) 2.90 (1.26)
TB gynoid Fat Mass (kg)b 6.64 (2.31) 5.64 (1.85) 4.85 (1.82)
Glucosec 6.2 (3.8) 6.2 (2.2) 5.6 (1.3)
Adjusted calcium 2.45 (0.07) 2.41 (0.10) 2.40 (0.08)
Phosphate 1.12 (0.18) 1.37 (0.86) 1.17 (0.44)
Alkaline phosphatase 74.9 (17.7) 86.7 (33.6) 85.2 (33.9)
P1NP (mg/L) 44.1 (30.0) 36.3 (19.9) 41.1 (23.4)
CTX (mg/L) 0.23 (0.18) 0.19 (0.13) 0.24 (0.17)
Osteocalcin (total) (mg/L) 15.7 (8.0) 15.6 (7.8) 17.8 (7.8)
Tibial trabecular bone density (mg HA/cm3)d 313.1 (59.8) 215.1 (40.9) 185 (41.5)
Tibial number of trabeculae (1/mm)d 2.83 (0.24) 2.31 (0.28) 2.25 (0.47)
Tibial trabecular thickness (mm)d 0.09 (0.02) 0.08 (0.01) 0.07 (0.01)
Tibial cortical thickness (mm)d 2.70 (1.07) 1.27 (0.43) 1.18 (0.33)
n (%) n (%) n (%)
Female 5 (45.5) 269 (77.5) 93 (65.8)
Postmenopausal 2 (40.0) 216 (80.3) 48 (51.6)
Estrogen replacement use (ever) 1 (20.0) 127 (47.2) 15 (16.1)
HBM¼high bone mass; TB¼ total body.
an¼ 468 for UK shoe size.
bTotal body DXA measures: n¼ 8 for LRP5 HBM, 199 for non-LRP5 HBM, 126 for controls.
cn¼ 247 for ﬁnger prick blood glucose.
dHRpQCTmeasures: n¼ 4 for LRP5 HBM, 59 for non-LRP5 HBM, 36 for controls. No LRP5 HBM cases reportedmalignancy; 2 LRP5 HBM cases, 7 non-LRP5
HBM cases, and 2 controls had ever used oral bisphosphonates.
p < 0.05, p < 0.001 when compared with LRP5 HBM case.
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genomeevolutionary rate proﬁling score (GERP) of 4.26 (Table 1).
rs143571358 has not been associated with any speciﬁc
phenotype to date and remains unvalidated in dbSNP. This
C>A variant lies within the coding sequence of SOST, and
introduces a stop codon at p.177. This is predicted by Mutation
Taster to be disease-causing because the remaining 37wild-type
amino acids are not incorporated in the mutated sclerostin
protein, potentially causing nonsense-mediated mRNA decay.
We also identiﬁed one previously reported SNP in exon 1 in
eight HBM cases (rs17882143, c.28G>A; p.Val10Ile, MAF
T¼ 0.047%), predicted to be benign by PolyPhen, tolerated by
SIFT, a polymorphism by Mutation Taster, and neutral by PMut;
as well as two intergenic SNPs in a further nine HBM cases
(8 cases with rs28548107 MAF G¼ 0.046%; 1 case with
rs181372199, MAF T¼ 0.043%). We found no variants in the
30 regulatory region of SOST to suggest VBD. No SOST variants
were identiﬁed in individuals with LRP5 variants (and vice versa).
LRP4
We foundnomutations in LRP4 exons 25 and 26. In oneHBMcase
we identiﬁed a novel intronic heterozygous variant 24 bases
before the start of exon 25 but not in the splice junction
(c.3364-24G>T). The common SNP rs2306033 (MAF 25% in 1000
Genomes) was observed in 56 (21%) HBM cases.
Discussion
This study represents the largest systematic approach to date to
identify the genetic cause of HBM, by screening all known HBM
loci in a well-deﬁned population drawn from the general
population, and has identiﬁed both novel and previously
reported variants underlying HBM. We have increased to 13
the number of LRP5 mutations associated with HBM, having
identiﬁed two novel and three previously reported missense
LRP5 mutations, associated with HBM in seven families. The
frequency of LRP5 variants in HBM individuals, therefore, is 7 in
258, less than 3%; if our DXA population is representative of the
general population, this extrapolates to an overall prevalence of
LRP5 HBM mutations in the UK of approximately 5 per 100,000.
We identiﬁed one person with moderate HBM and a novel
heterozygous nonsense SOST mutation predicted to prema-
turely truncate sclerostin, suggesting her to be a sclerosteosis
carrier. However, no cases fulﬁlled a clear clinical diagnosis of
autosomal recessive sclerosteosis with homozygous or com-
pound heterozygous mutations. We did not observe any LRP4
HBM variants in the limited number of exons sequenced. Our
ﬁndings highlight the rarity of mutations in established HBM loci
within the general population, and that the majority of HBM
cases remain genetically unexplained.
The clinical variability we observed in LRP5 HBM cases may
arise from genotype/phenotype correlation, as suggested by the
variable in silico functional consequences presented here.
The LRP5 p.Asn198Ser mutation, seen in our most extreme HBM
case with hip BMD Z-scores >þ10, has been reported in a family
with HBM and deafness, sensorimotor neuropathy, and spinal
stenosis,(6) features thatwedid notobserve. Our proteinmodeling
shows the direct implications of this mutation on SOST binding,
explaining the extreme bone phenotype. A disrupted LRP5-SOST
binding site would be expected to lead to a relative resistance to
sclerostin, with secondary increased sclerostin levels, an observa-
tion we have previously made in LRP5HBM.(43)Ourmost frequent
Table 3. Clinical Characteristics of LRP5 HBM Cases, Non-LRP5 HBM Cases, and Family Controls Adjusted for Age, Gender, Menopausal
Status, and Estrogen Replacement Therapy in Women, and Height
LRP5 HBM
(n¼ 11)
mean (95% CI)
Non-LRP5 HBM
(n¼ 347)
mean (95% CI)
Controls
(n¼ 200)
mean (95% CI)
Shoe sizea 8.04 (7.21–8.86) 7.47 (7.27–7.68) 7.25 (7.03–7.47)
Total hip BMD Z-score 6.18 (5.43–6.94) 2.89 (2.71–3.08) 0.54 (0.34–0.75)
L1 BMD Z-score 5.97 (5.08–6.87) 3.62 (3.4–3.84)
 0.42 (0.17–0.66)
TB BMD (mg/cm2)b 1.70 (1.64–1.77) 1.35 (1.33–1.37) 1.18 (1.16–1.20)
TB lean mass (kg)b 48.2 (43.8–52.6) 49.4 (48.3–50.5) 47.5 (46.3–48.6)
TB fat mass (kg)b 36.4 (28.3–44.5) 35.3 (33.3–37.2) 30.3 (28.1–32.4)
TB android fat mass (kg)b 3.39 (2.44–4.33) 3.46 (3.22–3.69) 2.88 (2.62–3.13)
TB gynoid fat mass (kg)b 6.45 (5.29–7.61) 5.59 (5.31–5.87) 5.1 (4.79–5.41)
Glucosec 6.1 (4.3–7.8) 6.2 (5.7–6.7) 6.0 (5.4–6.7)
Adjusted calcium 2.47 (2.42–2.53) 2.41 (2.39–2.42) 2.41 (2.40–2.43)
Phosphate 1.12 (0.72–1.51) 1.23 (1.14–1.33) 1.10 (0.99–1.20)
Alkaline phosphatase 74.1 (55.9–92.4) 81.0 (76.5–85.4) 84.2 (79.3–89.1)
P1NP (mg/L) 41.2 (28.5–54.0) 35.7 (32.6–38.8) 37.6 (34.2–41.1)
CTX (mg/L) 0.22 (0.12–0.31) 0.19 (0.17–0.22) 0.23 (0.20–0.25)
Osteocalcin (total) (mg/L) 18.4 (13.4–23.5) 17.1 (15.9–18.3) 19.5 (18.1–20.9)
Tibial trabecular bone density (mg HA/cm)d 296.4 (257.0–335.9) 210.9 (198.5–223.4) 175.2 (161.8–188.7)
Tibial number of trabeculae (1/mm)d 2.67 (2.33–3.00) 2.28 (2.17–2.38) 2.17 (2.06–2.29)
Tibial trabecular thickness (mm)d 0.09 (0.08–0.11) 0.08 (0.07–0.08) 0.07 (0.06–0.07)
Tibial cortical thickness (mm)d 2.54 (2.18–2.91) 1.28 (1.16–1.39) 1.05 (0.92–1.17)
HBM¼high bone mass; TB¼ total body.
an¼ 468 for UK shoe size.
bTotal body DXA measures: n¼ 8 for LRP5 HBM, 199 for non-LRP5 HBM, 126 for controls.
cn¼ 247 for ﬁnger-prick blood glucose.
dHRpQCT measures: n¼ 4 for LRP5 HBM, 59 for non-LRP5 HBM, 36 for controls.
p < 0.05, p < 0.001 when compared with LRP5 HBM cases.
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LRP5mutation (p.Ala242Thr), associated with BMD Z-scores þ3.1
toþ10.7, has been reported in ﬁveprevious families (two Portland
US, one Sardinia, one France, oneChina),(7,44) towhichwecannow
add a further three UK families.
We identiﬁed an isolated HBM case with an LRP5 p.Arg266Cys
variant; although having an allocated SNP ID, this SNP is not
validated, has no described MAF in dbSNP, is not listed in
ExAC/LOVD, and has not been described previously in associa-
tion with HBM (or any phenotype). Three of four in silico
prediction tools considered this variant to be functionally
deleterious, although protein modeling suggested an indirect
effect and/or altered protein folding. These less deleterious
Fig. 2. Structural models of the LRP5-SOST complex (A) with mutations; p.Asn198Ser (B), p.Ala242Thr (C), p.Arg266Cys (D), p.Gln89Arg (E), and
p.Thr173Met (F).
Fig. 1. Clinical imaging in LRP5 HBM. (A) Axial computed tomography image showing markedly thickened skull in male aged 30 years with p.Asn198Ser
substitution (pedigree 1). (B) Mandible enlargement in female aged 49 years with p.Ala242Thr substitution (pedigree 2). (C) Asymmetric mandible
enlargement with partial left cranial nerve V and VII impairment in female aged 21 years with p.Ala242Thr substitution (pedigree 3).
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effects are consistent with a milder, mostly asymptomatic HBM
phenotype (BMD Z-scores þ2.5 to þ6.5).
LRP5 mutation p.Gln89Arg was identiﬁed in one HBM case
(no DNA was available from relatives). Interestingly p.Gln89Arg
was also identiﬁed in one of the ﬁrst reported LRP5 HBM case
series.(7)However, this variant has been reportedwithMAF 8% in
the Japanese population.(45) Subsequently, p.Gln89Arg was
associated with lower (not higher) femoral neck BMD in young
Korean men (with MAF 19%)(46) and postmenopausal Han
Chinese women (with MAF 17%).(47) However, this association
with low BMD was not seen at the lumbar spine,(46,47) nor in 321
postmenopausal Japanese women, in whom it was instead
associated with spinal osteophytes.(48) Importantly functional
analyses suggest that p.Gln89Arg does not play a functional role
in canonical Wnt signaling.(49) Whether p.Gln89Arg shares a
rare haplotype with a functional BMD allele speciﬁcally in white
populations is unknown.
LRP5 mutation p.Thr173Met, identiﬁed in one isolated HBM
case, was previously reported in association with abnormal
retinal vasculature/folds in an older British woman diagnosed
with familial exudative vitreoretinopathy (FEVR); however, her
BMDwas not reported.(50) Although SIFT and PMut consider this
mutation to be tolerated/neutral, respectively, PolyPhen and
Mutation Taster predict it to be “probably damaging” and
“disease causing,” with a moderate conservation score (GERP
1.67, Table 1). LRP5 HBM mutations are considered fully
penetrant; however, phenotypes may vary even within an
individual family, as is seen in many genetic conditions; eg,
osteogenesis imperfecta.
Originally LRP5 expression studies identiﬁed reduced afﬁnity
of DKK1 for LRP5 as the mechanism underlying LRP5 HBM.(51)
The only previous LRP5 protein modeling to date (using
p.Asn198Ser and p.Ala242Thr mutations, although without
modeling the mutant side chains) predicted that both Wnt
inhibitors DKK1 and SOST act through a common site in the ﬁrst
b-propeller. This supports our models describing both
LRP5-SOST and LRP5-DKK1 interactions.(41) Furthermore, func-
tional studies support p.Asn198Ser diminishing LRP5-SOST
binding; although LRP5-DKK1 may be differentially affected.(52)
However, more recently SOST has emerged as the key LRP5
regulator.(53) Genetic variance within both SOST and LRP5
are associated with BMD in the general population, hence
mechanistic insights can have application to the wider
population.(54–56) The extent to which common genetic
variation in all BMD-associated genes, explains the HBM
phenotype in non-LRP5 HBM remains a question of interest.
Although absolute numbers are small, this remains one of the
largest mutationally heterogeneous collections of LRP5 HBM
cases to date. Though the severity of the clinical phenotype
varied according to the precise mutation, as a group, individuals
with LRP5 mutations appear to have a more extreme HBM
phenotype when compared to other HBM individuals. We have
previously reported that HBM individuals have greater trabecu-
lar BMD and cortical thickness as assessed by pQCT.(57) In the
present study we performed HRpQCT in a small subgroup;
trabecular BMD and cortical thickness appeared to be higher in
LRP5 HBM compared to non-LRP5 HBM cases. The increased
sclerostin levels reported in LRP5 HBM relative to other HBM
cases, likely represents a compensatory response.(43) Bone
turnover appeared similar among LRP5 HBM, non-LRP5 HBM,
and controls (with low coefﬁcients of variation).(34) This null
ﬁnding might reﬂect the small sample size. However, it is also
likely that single time point sampling may not reﬂect
accumulated life-course exposure to anabolic stimuli. We lacked
bone turnover assessment during peak bone mass accrual,
during which time the effect of anabolic mutations might be
expected to be maximal. Interestingly, two LRP5 HBM cases
(p.Arg266Cys; p.Asn198Ser) still had high BMD despite
long-term glucocorticoid use; whether anabolic LRP5mutations
confer a relative resistance to glucocorticoid-induced osteopo-
rosis remains to be determined, but if so, it would be of great
pharmacotherapeutic interest.
Fat mass was increased in individuals with LRP5 HBM
mutations, as we previously reported for HBM individuals
overall.(34) However, we observed a particular preponderance
toward a gynoid fat mass distribution, persisting even after
adjustment for body weight, in LRP5 HBM compared with both
non-LRP5 HBM and controls. This contrasts with the android fat
phenotype we have previously indentiﬁed in HBM women (98%
of whom have non-LRP5 HBM).(34) Recent mechanistic analyses
have shown LRP5 HBM mutations, in some of the individuals
reported here, lead to gluteofemoral fat accumulation due to
altered LRP5-dependent transcription in site-speciﬁc depots,
which raises interesting metabolic implications for medicines
that modulate Wnt activity.(58)
Our study has limitations. The rarity of LRP5 HBM challenged
our sample size, restricted our ability to stratify (eg, by
gender), and limited the conﬁdence with which we can make
prevalence estimates, it further prevented a clustered analysis,
although evidence of intrafamilial clustering has previously
been small.(30) Furthermore, not all pedigrees had access to
total body DXA and HRpQCT assessment, nor were full
pedigrees able to be recruited in all cases. Interestingly, three
spouses fulﬁlled HBM index case criteria, suggestive of
assortative mating, as reported.(30) Sequencing was restricted
to exons in which anabolic mutations have been reported; and
we have reported all identiﬁed variants. It is possible that
variants in other b-propeller regions may contribute to HBM;
however, this seems less likely because mutations in the
remaining b-propellers have only been associated with FEVR
and OPPG to date. Our approach was a practical one given the
size of LRP5 and exon 2 of SOST. We did not sequence for DKK1
mutations; a novel missense mutation in the LRP5 inhibitor
DKK1 (c.74Y>F) has recently been reported to segregate with
HBM in one Spanish family.(59) Nor did we sequence CLCN7
(associated with autosomal dominant osteopetrosis type 2) or
genes associated with the more severe autosomal recessive
forms of osteopetrosis (eg, TNFSF11s, TCIRG1, and PLEKHM1)
because clinical and radiological phenotyping excluded
diagnoses of osteopetrosis. The increasing availability and
affordability of whole-exome sequencing will allow compre-
hensive screening of all known anabolic and osteopetrotic loci
simultaneously in similar future studies.
Conclusions
We identiﬁed ﬁve missense LRP5 mutations and one novel
nonsense SOST mutation, in the largest population study of
HBM to date. Protein modeling suggests the severity of high
BMD corresponds to the degree of predicted LRP5 protein
disruption. However, these LRP5 and SOST HBM cases account
for only a small proportion (3%) of HBM, raising the
possibility that either mutations in novel HBM genes or
polygenic inheritance is largely responsible for most cases of
HBM in the population.
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